Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James Brian Windsor
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Beta
- 1.37
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -9.04
Financials
Net Income
$-6.38MEBITDA
$-6.38MFree Cash Flow
$-8.64MEPS (diluted)
$-0.21Shares Outstanding (diluted)
30.35M+568.5%Operating Expenses
$6.08MCash & Debt
$40.65MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-49.87M | $-1.96 |
| 2024 | $0.00 | $-62.88M | $-3.51 |
| 2023 | $0.00 | $-15.7K | $-3.42 |
| 2022 | $0.00 | $-27.3K | $-6.02 |
| 2021 | $0.00 | $-26.2K | $-5.89 |
| 2020 | $0.00 | $-21.2K | $-0.00 |
Valuation
RNTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·32d ago·Neutral
Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain.
View source ↗ - Newszacks.com·32d ago·Neutral
Here's Why You Should Add RNTX Stock to Your Portfolio Now Rein Therapeutics advances LTI-03 in IPF. RENEW enrollment tops 25%, with interim data expected in the fourth quarter of 2026.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update AUSTIN, Texas, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.10 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.10 vs $-0.17beat
- Fri, May 15$-0.19 vs $-0.49beat
- Thu, Mar 26$-1.09 vs $-1.09beat
- Fri, Nov 14$-0.21 vs $-0.24beat
- Thu, Aug 14$-0.28 vs $-0.22miss
- Mon, Apr 7$-0.26 vs $-0.14miss
Estimates and results for RNTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RNTX officers and directors.
- Bought
- $626k
- Sold
- —
10 trades
0 trades
- Von Rickenbach Josef Hbought
- Von Rickenbach Josef Hbought
- Von Rickenbach Josef Hbought
- Von Rickenbach Josef Hbought
- Windsor James Brianbought
- Voss Capital, Lpbought
- Voss Capital, Lpbought
- Voss Capital, Lpbought
8 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RNTX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.